Comparative Pharmacology
Head-to-head clinical analysis: PULMOTECH MAA versus SODIUM IODIDE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PULMOTECH MAA versus SODIUM IODIDE I 123.
PULMOTECH MAA vs SODIUM IODIDE I 123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PULMOTECH MAA is a biologic agent that selectively inhibits the interleukin-5 (IL-5) signaling pathway by binding to the IL-5 receptor alpha subunit on the surface of eosinophils, thereby blocking eosinophil maturation, activation, and survival. This reduces eosinophil-mediated inflammation in the airways.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
4 mg IV every 6 hours; administer over 30 minutes.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
None Documented
None Documented
Terminal elimination half-life is 12 ± 3 hours. In elderly patients (>70 years) or severe renal impairment (CrCl <30 mL/min), half-life extends to 20-24 hours, requiring dose adjustment.
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Renal excretion accounts for 65% (20% unchanged, 45% as metabolites); biliary/fecal excretion accounts for 30% (primarily conjugates); 5% exhaled as CO2.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical